Research
Hormonal
Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.
Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.
StrongSupportsmedium confidence
Over the 10-year period, we estimated that broad access to semaglutide would result in 38 950 cardiovascular events avoided, and 6180 deaths avoided due to reduction in cardiovascular events and improvement in chronic kidney disease or metabolic-associated steatohepatitis progression.
Why this rating
The study uses data from government reports, clinical studies, and real-world claims, indicating a robust methodology.
Source
Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare
Victoria Dayer et al. · Value in Health · 2025
DOI 10.1016/j.jval.2025.07.007
otherCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →